pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Eli Lilly and Co · news · pharmadog
← back to Eli Lilly and Co
News mentioning Eli Lilly and Co
123
stories
20h
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
biospace
21h
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
biopharma dive
3d
Foghorn cuts 40% of workforce
biospace
3d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
4d
3 takeaways from a European obesity scientific meeting
biopharma dive
4d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
4d
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
biospace
5d
The top 12 companies hiring in biopharma now
biospace
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
6d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
8d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
biospace
10d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
11d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
11d
STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more
stat
11d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
11d
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
biospace
13d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
13d
9 companies hiring in Pennsylvania now
biospace
13d
Pharmas face off for manufacturing talent amidst reshoring efforts
biospace
13d
STAT+: Did the Trump administration just cut Novo a huge financial win?
stat
13d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
13d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
13d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
13d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
18d
Fed rate hike won’t hold biotech down despite climbing capital costs
biospace
19d
Trending: Top biopharma disciplines with jobs live now
biospace
19d
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
← prev
page 1 of 5
next →
